Innoviva

INVA

Market cap $1.22B

Overview Fund Activity

19.38 USD

+0.04

0.21%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

19.38

0.00

0%

1 day

0.21%

5 days

-2.42%

1 month

-6.74%

3 months

-9.61%

6 months

10.55%

Year to date

11.38%

1 year

-1.67%

5 years

66.93%

10 years

91.88%

About: Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.

Employees: 127

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

96% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 24

33% more repeat investments, than reductions

Existing positions increased: 105 | Existing positions reduced: 79

19% more capital invested

Capital invested by funds: $1.24B [Q1] → $1.47B (+$234M) [Q2]

8.6% more ownership

Funds ownership: 108.28% [Q1] → 116.88% (+8.6%) [Q2]

7% more funds holding

Funds holding: 244 [Q1] → 262 (+18) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]

94% less call options, than puts

Call options by funds: $207K | Put options by funds: $3.25M

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$26

34% upside

Avg. target

$35

82% upside

High target

$45

132% upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

Oppenheimer Trevor Allred	$35	Outperform Initiated	11 Aug 2025
HC Wainwright & Co. Raghuram Selvaraju	$45	Buy Maintained	11 Aug 2025
Cantor Fitzgerald Steve Seedhouse	$26	Overweight Initiated	11 Jul 2025

See Analyst Rankings

Financial journalist opinion

Innoviva, Inc. (INVA) Presents At Citi's Biopharma Back To School Conference Transcript

Innoviva, Inc. (NASDAQ:INVA ) Citi's Biopharma Back to School Conference September 2, 2025 1:45 PM EDT Company Participants Pavel Raifeld - CEO & Director Conference Call Participants Jason Jun - Citi Presentation Jason Jun Well, thanks for joining, everyone. Today with us, we have Pavel Raifeld, the CEO of Innoviva.

Innoviva, Inc. (INVA) Presents At Citi's Biopharma Back To School Conference Transcript

Innoviva to Participate in Upcoming Investor Conferences

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in September: Citi's 2025 Biopharma Back to School Conference Format: Fir.

Innoviva to Participate in Upcoming Investor Conferences

Innoviva Specialty Therapeutics' Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award

WALTHAM, Mass.--(BUSINESS WIRE)--Prix Galien Award 2025.

Innoviva Specialty Therapeutics' Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award

The Motley Fool

Innoviva (INVA) Q2 Sales Jump 64%

Innoviva (INVA -1.03%), a pharmaceutical company specializing in royalties and specialty therapeutics, reported second-quarter earnings on August 6, 2025. The company announced earnings per share (GAAP) of $0.77 on $100.3 million in revenue.

Innoviva (INVA) Q2 Sales Jump 64%

Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the second quarter ended June 30, 2025, and highlighted select corporate progress and achievements. “Innoviva continued to deliver i.

Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress

FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

WALTHAM, Mass. & GENEVA--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for zoliflodacin, an investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in.

FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

WALTHAM, Mass. & GENEVA, Switzerland--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for zoliflodacin, the investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adul.

Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

Innoviva to Participate in Upcoming Investor Conferences

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today announced that management will participate in the following upcoming investor conferences in June: Goldman Sachs 46th Annual Global Healthcare Conference 2025 Form.

Innoviva to Participate in Upcoming Investor Conferences

ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced the United States commercial availability of ZEVTERA® (ceftobiprole medocaril sodium for injection), the newest addition to the Company's growing antibiotic portfolio. ZEVTERA is the only U.S. Food and Drug Administration (FDA) approved advanced-generation cephalosporin indicated to treat adult patients with Staphylococcus aureus bloodstream infection (bacteremi.

ZEVTERA® (ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic Now Commercially Available in the U.S. to Treat Three Types of Bacterial Infections

Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States

Allschwil, Switzerland, May 20, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that its antibiotic Zevtera® (ceftobiprole medocaril for injection) is now commercially available in the United States through Basilea's partner Innoviva Specialty Therapeutics, Inc., a wholly owned subsidiary of Innoviva, Inc. (NASDAQ: INVA). Zevtera is used in hospitals for the treatment of bacterial infections, such as those caused by Staphylococcus aureus bacteria, including methicillin-resistant strains (MRSA).

Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States

See News Rankings

Charts implemented using Lightweight Charts™